At a glance
ClinicalIndex Comparison RecordN/ACompleted· 126 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effect of Growth Hormone Receptor Antagonism and Somatostatin Analog Administration on Quality of Life
In Brief
An observational study for Acromegaly. Completed, enrolled 126 participants across 1 site.
Detailed Summary
The investigators hypothesize that treatment of acromegaly will be associated with an improvement in quality of life compared to active acromegaly. At the same time, they will also be studying the effects of different acromegaly treatments on the quality of life.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsAcromegaly
CountriesUnited States
CollaboratorsPfizer
Timeline
N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedNov 2012
Enrollment StartJan 2013
Primary CompletionDec 2016
TodayJul 2026
First PostedNov 22, 2012
Enrollment StartJan 1, 2013
Primary CompletionDec 19, 2016
TodayJul 2, 2026
Enrollment to primary: 4.0 yearsPosted 13.6 years ago